ES2092514T3 - Conjugados de anticuerpos de dominio variable. - Google Patents

Conjugados de anticuerpos de dominio variable.

Info

Publication number
ES2092514T3
ES2092514T3 ES90917572T ES90917572T ES2092514T3 ES 2092514 T3 ES2092514 T3 ES 2092514T3 ES 90917572 T ES90917572 T ES 90917572T ES 90917572 T ES90917572 T ES 90917572T ES 2092514 T3 ES2092514 T3 ES 2092514T3
Authority
ES
Spain
Prior art keywords
variable domain
domain antibodies
conjugates
linker
specific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90917572T
Other languages
English (en)
Inventor
Paul James Davis
Martine Elisa Verhoeyen
Winter Ronald Franks Jacabu De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever NV
Original Assignee
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever NV filed Critical Unilever NV
Application granted granted Critical
Publication of ES2092514T3 publication Critical patent/ES2092514T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Weting (AREA)

Abstract

PEQUEÑAS MOLECULAS LIGADORAS ESPECIFICAS, COMO ANTICUERPOS DE DOMINIO UNICO VARIABLE (DABS) Y FRAGMENTOS DE FV, PUEDEN ACOPLARSE A SUPERFICIES DE PLASTICOS SOLIDOS O A INDICADORES COMO ENZIMAS POR MEDIO DE LIGADORES QUE INCLUYEN POLIPEPTIDOS QUE CONTIENEN ENTRE 5 Y 20 AMINOACIDOS Y QUE SON HIDROFOBICOS Y/O CONTIENEN POR LO MENOS UN RESIDUO DE LISINA. EL ACOPLAMIENTO PUEDE REALIZARSE SIN UNA PERDIDA SIGNIFICATIVA DE ACTIVIDAD LIGADORA ESPECIFICA. EL COMBINADO DAB/LIGADOR O FU/LIGADOR PUEDE PREPARARSE MEDIANTE LA EXPRESION EN ORGANISMOS MODIFICADOS GENETICAMENTE.
ES90917572T 1989-12-01 1990-11-27 Conjugados de anticuerpos de dominio variable. Expired - Lifetime ES2092514T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898927230A GB8927230D0 (en) 1989-12-01 1989-12-01 Reagents

Publications (1)

Publication Number Publication Date
ES2092514T3 true ES2092514T3 (es) 1996-12-01

Family

ID=10667290

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90917572T Expired - Lifetime ES2092514T3 (es) 1989-12-01 1990-11-27 Conjugados de anticuerpos de dominio variable.

Country Status (8)

Country Link
EP (1) EP0456790B1 (es)
JP (1) JPH0833397B2 (es)
AT (1) ATE141415T1 (es)
AU (1) AU650857B2 (es)
DE (1) DE69028094T2 (es)
ES (1) ES2092514T3 (es)
GB (1) GB8927230D0 (es)
WO (1) WO1991008482A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
GB9012995D0 (en) * 1990-06-11 1990-08-01 Celltech Ltd Multivalent antigen-binding proteins
GB9226535D0 (en) * 1992-12-21 1993-02-17 Unilever Plc Foodstuffs and other compositions
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
EP0736770A3 (fr) * 1995-04-05 1997-05-02 Anda Biolog Sa Conjugué immunoréactif, procédé d'obtention de ce conjugué, anticorps dirigés contre ledit conjugué, composition pharmaceutique et dispositif de diagnostic les comprenant
BR9907950A (pt) * 1998-02-19 2001-12-18 Xcyte Therapies Inc Composições e processos para regulagem deativação de linfócitos
AU776824B2 (en) 1999-04-22 2004-09-23 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
WO2001040310A2 (en) * 1999-11-29 2001-06-07 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (da) * 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0134307B1 (de) * 1983-07-29 1989-04-19 Henning Berlin GmbH Chemie und Pharmawerk Voraktivierte Kunststoffoberflächen zur Immobilisierung von organisch-chemischen und biologischen Materialien, Verfahren zur Herstellung und Verwendung derselben
DE3640412A1 (de) * 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
SE8701962D0 (sv) * 1987-05-13 1987-05-13 Bo Hakan Nygren Sett att isolera och/eller bestemma halten av ett organiskt emne genom kovalent koppling av en for emnet specifik motreaktant till ytadsorberad, hydrofoberad vattenloslig polymer
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
IT1223320B (it) * 1987-10-23 1990-09-19 Eniricerche Spa Sensore con membrana immunochimica legata chimicamente a un dispositivo semiconduttore
US4952519A (en) * 1988-05-02 1990-08-28 E. I. Du Pont De Nemours And Company Protein immobilization with poly(ethyleneimine) derivatized with a hydroprobic group

Also Published As

Publication number Publication date
JPH04504309A (ja) 1992-07-30
EP0456790B1 (en) 1996-08-14
AU650857B2 (en) 1994-07-07
WO1991008482A1 (en) 1991-06-13
AU6877591A (en) 1991-06-26
ATE141415T1 (de) 1996-08-15
JPH0833397B2 (ja) 1996-03-29
DE69028094D1 (de) 1996-09-19
GB8927230D0 (en) 1990-01-31
DE69028094T2 (de) 1997-02-20
EP0456790A1 (en) 1991-11-21

Similar Documents

Publication Publication Date Title
AU6113396A (en) Novel high affinity human antibodies to tumor antigens
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
WO1993021331A3 (en) Polysaccharide binding fusion proteins and conjugates
AU7366687A (en) Coupling agents for radiolabeling proteins
PT1135498E (pt) Variantes de anticorpos com maior afinidade de ligação em comparação com os anticorpos parentais
ES2171705T3 (es) Complejos de polipeptido-dendrimero.
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
ATE383430T1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
ATE152918T1 (de) Technetium-99m-markierte peptide zur bilderzeugung
PT76394A (fr) Procede de preparation de nouveaux conjugues associant par liaison covalente une enzyme et un anticorps
PT762901E (pt) Peptidos marcados com tecnecio-99m para imagiologia.
DE69942802D1 (de) Trifunktionales reagenz zur verbindung von biomolekülen
ES2092514T3 (es) Conjugados de anticuerpos de dominio variable.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
HK1037728A1 (en) Enzyme-protein complex
CA2200855A1 (en) Radioactive phosphorous labeling of proteins for targeted radiotherapy
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
ATE285474T1 (de) Haemophilus adhäsionsproteinen
ES2150443T3 (es) Derivados de benzodiazepina y conjugados proteicos y polipeptidicos de los indicados derivados.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ES8604228A1 (es) Procedimiento para la obtencion de un conjugado entre un io-nofero carboxilico monovalente y una macromolecula
ATE66534T1 (de) Nortriptylinderivate, verfahren zu ihrer herstellung, deren konjugate mit antigenischen proteinen und enzymen, antikoerper davon und verwandte verfahren zur bestimmung.
PT524421E (pt) Herpesvirus humano tipo 6 proteina p 100, sequencias de adn correspondentes, preparacao e utilizacao
DE69631624D1 (de) Antikörper gegen menschliches restrictin
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 456790

Country of ref document: ES